I’d like to share some information about emerging research on potential cancer therapies that are being studied in the lab and early clinical settings. Recent exploratory studies have examined how existing medications—such as ivermectin and fenbendazole—may interact with cancer cells. While these findings are preliminary and not yet approved as cancer treatments, they are prompting scientific curiosity and further research.
It’s important to remember that these are not substitutes for standard medical care. However, staying informed about new developments allows you to have thoughtful, evidence-based discussions with your oncology team.
I’ve prepared a short PDF that summarizes the studies currently under review, so you can explore the science yourself and better understand what’s being studied.
ABOUT IVERMECTIN AND COVID
While ivermectin is widely known as an antiparasitic—commonly used for conditions like malaria—its potential antiviral, anti-inflammatory, and even anticancer properties are still being explored.
From the literature, we know that when taken at 0.2 mg per kg (typically twice daily for five days), ivermectin may help prevent COVID-19 if used before exposure—for example, if a household member just tested positive or after recent travel. However, large studies in Malaysia and Brazil found no significant benefit when ivermectin was given a week after infection. Timing and proper dosing appear to be key.
